Price cut leads NICE to back Novo Nordisk’s obesity drug Sax...

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management.

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly